Business
Moderna’s stock has surged 488% in 2020: Is it a buy for 2021?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
All eyes were on the biotech Moderna (NASDAQ: MRNA) in 2020. It wasn’t quite a popular name in the pharmaceutical space, as it has no approved products on the market yet. But its sudden entry in the COVID-19 vaccine competition grabbed a lot of attention, and it became the second company to win approval in a race with dozens of players. No wonder its stock has surged 488% so far this year, while the S&P 500 has gained 16%.
On Dec. 11, Pfizer (NYSE: PFE) and its German biotech partner BioNTech (NASDAQ: BNTX) became the…
-
General17 hours agoTributes flow after Australian Paralympic bronze medallist Nicholas Hum dies aged 32
-
General13 hours agoNT’s top year 12 achievers celebrated, with some looking to pursue teaching careers
-
General13 hours agoReuven Morrison was killed in the Bondi Beach shooting one year after warning about antisemitism
-
Noosa News22 hours agoThree taken to hospital, crime scene declared after unit fire in Spring Hill